Lupus Nephritis clinical trials
The registry lists 340 studies for Lupus Nephritis across more than 10 countries. 135 are recruiting or about to start. 305 of them are mainly about Lupus Nephritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Lupus Nephritis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Assiut University (22) · Novartis Pharmaceuticals (10) · Nanjing University School of Medicine (8) · Aurinia Pharmaceuticals Inc. (8) · Hoffmann-La Roche (7) · RenJi Hospital (6) · Sohag University (6) · Sun Yat-sen University (5)
What is being tested here
Drugs under test in Lupus Nephritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Mycophenolic Acid | 7 | 7 | 23 |
| Cyclophosphamide | 5 | 0 | 10 |
| Voclosporin | 3 | 4 | 9 |
| Dapagliflozin | 3 | 0 | 6 |
| Obinutuzumab | 3 | 2 | 5 |
| YTS109 | 3 | 0 | 4 |
| Fludarabine | 3 | 0 | 3 |
| Rituximab | 2 | 4 | 7 |
| Belimumab | 2 | 3 | 5 |
| Belacabnagene franleucel | 2 | 0 | 2 |
Drug classes tested here Alkylating agents 5 open · Antimetabolites 3 open · Corticosteroids 2 open · Calcineurin inhibitors 1 open · Proteasome inhibitors 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Feb 2027Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis · Phase 3 · AstraZeneca
- Jun 2027A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Sep 2027Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis · Phase 3 · Novartis Pharmaceuticals
- Nov 2026An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Dec 2026A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus · Hospital for Special Surgery, New York
- Dec 2026A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease · Adicet Therapeutics
- Dec 2026The Relation Between Serum Zinc and Lupus Nephritis · Assiut University
- Dec 2026Molecular Biomarkers for Discriminating Lupus Nephritis in SLE · Egyptian Chinese University
- Dec 2026The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population · Ahmed Yehia Ismail
- Dec 2026Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis · Nanjing University
Who these studies take
Of the 88 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 51 (58%) stop at 75 or younger. 29 (33%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 7 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 15 (17%) | 15 (17%) |
| 18 | 86 (98%) | 85 (97%) |
| 30 | 81 (92%) | 80 (91%) |
| 40 | 80 (91%) | 79 (90%) |
| 50 | 80 (91%) | 79 (90%) |
| 65 | 77 (88%) | 76 (86%) |
| 75 | 45 (51%) | 44 (50%) |
| 85 | 34 (39%) | 33 (38%) |
Across all 340 studies, recruiting or not: 57% stop at 75 or younger and 30% at 65; 25% take children; 2% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Lupus Nephritis studies take
Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 40 mo28–57 · 33 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- Lupus Nephritis Care PathwayOct 19, 2026NCT07783152
Stopped2
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VTerminatedOct 15, 2026NCT05268289
- A Clinical Study of YTS109 Cell in R/R Systemic Lupus ErythematosusTerminatedOct 14, 2026NCT06943937
Newly registered4
- Molecular Biomarkers for Discriminating Lupus Nephritis in SLENov 10, 2026NCT07930091
- Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus ErythematosusOct 29, 2026NCT07902622
- MYTP01 for Immune-Mediated DiseasesOct 28, 2026NCT07901764
- A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesOct 14, 2026NCT07873931
Studies
Recruiting first, then most recently updated. Showing 50 of 340. Browse all 340 → or search them.
- Molecular Biomarkers for Discriminating Lupus Nephritis in SLENot yet recruitingNCT07930091
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingNCT06711887Phase 318 countries
- Dapagliflozin in Active Lupus NephritisRecruitingNCT07323524Phase 41 country
- MYTP01 for Immune-Mediated DiseasesNot yet recruitingNCT07901764Not applicable1 country
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruitingNCT05039619Phase 212 countries
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingNCT06434363Phase 1/21 country
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseRecruitingNCT07085104Phase 12 countries
- Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)RecruitingNCT07053800Phase 25 countries
- CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus ErythematosusNot yet recruitingNCT07659704Phase 1/21 country
- Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus ErythematosusRecruitingNCT079026221 country
- Study of Systemic Lupus ErythematosusRecruitingNCT000013721 country
- Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisRecruitingNCT06975787Phase 16 countries
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseRecruitingNCT06925542Phase 13 countries
- A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07104721Phase 11 country
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesRecruitingNCT07123519Phase 11 country
- LUPKYNIS Drug-use Results SurveyRecruitingNCT070538911 country
- Lupus Nephritis Care PathwayRecruitingNCT07783152Not applicable1 country
- A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingNCT07598396Phase 26 countries
- A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 16 countries
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard TherapyNot yet recruitingNCT07729826Phase 2
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusRecruitingNCT06121297Phase 1/23 countries
- Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus NephritisRecruitingNCT07799116Phase 1/21 country
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GRecruitingNCT06419205Phase 22 countries
- A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesEnrolling by invitationNCT07038447Phase 14 countries
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingNCT06839976Phase 1/21 country
- Diastolic Dysfunction and Inflammatory Biomarkers in Lupus NephritisNot yet recruitingNCT07837544
- A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus NephritisRecruitingNCT07328581Phase 21 country
- VIBRANT: VIB4920 for Active Lupus NephritisRecruitingNCT05201469Phase 21 country
- High Quality Evidence of Chinese Lupus Nephritis (HELP)RecruitingNCT030019731 country
- The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyRecruitingNCT05538208Phase 21 country
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisRecruitingNCT07570862Phase 21 country
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingNCT06897930Phase 1/24 countries
- Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus ErythematosusNot yet recruitingNCT07805863
- Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus Nephritis: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and C Reactive Protein to Serum Albumin RatioNot yet recruitingNCT07783711
- A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)Not yet recruitingNCT07767188Phase 31 country
- SII and SIRI as Prognostic Biomarkers in Lupus NephritisNot yet recruitingNCT07780045
- Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem CellsRecruitingNCT03673748Phase 21 country
- Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.Not yet recruitingNCT07763821
- Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and PrednisoloneRecruitingNCT07760480Phase 41 country
- PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisRecruitingNCT07611214Phase 41 country
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentRecruitingNCT07201129Phase 31 country
- CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAHRecruitingNCT06947460Phase 1/21 country
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune DiseaseNot yet recruitingNCT07729995Phase 11 country
- Wellness & Workforce Solution for Lupus/Lupus NephritisRecruitingNCT06217107Not applicable1 country
- Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II TrialNot yet recruitingNCT07721363Phase 21 country
- Neutrophil Extracellular Traps and Lupus NephritisNot yet recruitingNCT07721857
- Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)RecruitingNCT07719140Phase 41 country
- Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus NephritisNot yet recruitingNCT077193221 country
- Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus NephritisNot yet recruitingNCT07706998Not applicable1 country
- The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis PopulationRecruitingNCT07700940Phase 41 country